{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:57:58Z","timestamp":1789747078927,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2014ZX09507007-003"],"award-info":[{"award-number":["2014ZX09507007-003"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2014ZX09507007-001"],"award-info":[{"award-number":["2014ZX09507007-001"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32302884"],"award-info":[{"award-number":["32302884"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21771022"],"award-info":[{"award-number":["21771022"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2024QH546"],"award-info":[{"award-number":["ZR2024QH546"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023QC171"],"award-info":[{"award-number":["ZR2023QC171"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ejmech.2025.117593","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T18:46:39Z","timestamp":1743965199000},"page":"117593","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Discovery of potent focal adhesion kinase (FAK) inhibitor A8 with enhanced antitumor activity"],"prefix":"10.1016","volume":"291","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8407-2869","authenticated-orcid":false,"given":"Ye","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4950-8058","authenticated-orcid":false,"given":"Huabei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejmech.2025.117593_bib1","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.addr.2010.11.001","article-title":"Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis","volume":"63","author":"Zhao","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"Pt 8","key":"10.1016\/j.ejmech.2025.117593_bib2","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1242\/jcs.00373","article-title":"Focal adhesion kinase: the first ten years","volume":"116","author":"Parsons","year":"2003","journal-title":"J. Cell Sci."},{"issue":"9","key":"10.1016\/j.ejmech.2025.117593_bib3","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nrc3792","article-title":"FAK in cancer: mechanistic findings and clinical applications","volume":"14","author":"Sulzmaier","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.ejmech.2025.117593_bib4","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.3390\/cancers11111683","article-title":"Role of focal adhesion kinase in small-cell lung cancer and its potential as a therapeutic target","volume":"11","author":"Aboubakar Nana","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.117593_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215585","article-title":"DGKA interacts with SRC\/FAK to promote the metastasis of non-small cell lung cancer","volume":"532","author":"Fu","year":"2022","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117593_bib6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41568-021-00340-6","article-title":"Targeting FAK in anticancer combination therapies","volume":"21","author":"Dawson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.ejmech.2025.117593_bib7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41523-021-00263-3","article-title":"FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity","volume":"7","author":"Timbrell","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"6219","key":"10.1016\/j.ejmech.2025.117593_bib8","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1126\/science.347.6219.226","article-title":"The cancer stem cell gamble","volume":"347","author":"Kaiser","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.117593_bib9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/377539a0","article-title":"Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice","volume":"377","author":"Du\u0161ko lli\u0107","year":"1995","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117593_bib10","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1158\/0008-5472.CAN-08-3078","article-title":"Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem\/progenitor cells","volume":"69","author":"Luo","year":"2009","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117593_bib11","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41467-018-02938-1","article-title":"Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase","volume":"9","author":"Thiagarajan","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117593_bib12","doi-asserted-by":"crossref","first-page":"51733","DOI":"10.18632\/oncotarget.18517","article-title":"Inhibition of FAK kinase activity preferentially targets cancer stem cells","volume":"8","author":"Kolev","year":"2017","journal-title":"Oncotarget"},{"issue":"83","key":"10.1016\/j.ejmech.2025.117593_bib13","first-page":"1","article-title":"Focal adhesion kinase: from biological functions to therapeutic strategies","volume":"12","author":"Ximin Tan","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.117593_bib14","first-page":"1","article-title":"Focal adhesion kinase-mediated interaction between tumor and immune cells in the tumor microenvironment: implications for cancer-associated therapies and tumor progression","author":"Kwantwi","year":"2024","journal-title":"Clin. Transl. Oncol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117593_bib15","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/(SICI)1097-0215(19961009)68:2<169::AID-IJC4>3.0.CO;2-W","article-title":"Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma","volume":"68","author":"Tremblay","year":"1996","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.ejmech.2025.117593_bib16","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ccell.2019.01.007","article-title":"Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance","volume":"35","author":"Cooper","year":"2019","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ejmech.2025.117593_bib17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13046-019-1056-8","article-title":"Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells","volume":"38","author":"Rigiracciolo","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.ejmech.2025.117593_bib18","doi-asserted-by":"crossref","first-page":"14382","DOI":"10.1021\/acs.jmedchem.0c01248","article-title":"Progress in the development of small molecular inhibitors of focal adhesion kinase (FAK)","volume":"63","author":"Lu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117593_bib19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.lungcan.2019.10.033","article-title":"Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer","volume":"139","author":"Gerber","year":"2020","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.ejmech.2025.117593_bib20","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1093\/annonc\/mdw427","article-title":"A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors","volume":"27","author":"Soria","year":"2016","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117593_bib21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11523-019-00620-0","article-title":"Phase I study of the focal adhesion kinase inhibitor BI 853520 in Japanese and Taiwanese patients with advanced or metastatic solid tumors","volume":"14","author":"Doi","year":"2019","journal-title":"Targeted Oncol."},{"issue":"13","key":"10.1016\/j.ejmech.2025.117593_bib22","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1200\/JCO.2011.38.9346","article-title":"Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors","volume":"30","author":"Infante","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117593_bib23","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1200\/JCO.21.02371","article-title":"Alliance A071401: phase II trial of focal adhesion kinase inhibition in meningiomas with somatic NF2 mutations","volume":"41","author":"Priscilla","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117593_bib24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s13046-019-1265-1","article-title":"The roles of nuclear focal adhesion kinase (FAK) on Cancer: a focused review","volume":"38","author":"Zhou","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117593_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.820446","article-title":"A FAK inhibitor boosts anti-PD1 immunotherapy in a hepatocellular carcinoma mouse model","volume":"12","author":"Wei","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"16","key":"10.1016\/j.ejmech.2025.117593_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202100250","article-title":"Focal adhesion kinase (FAK) inhibition synergizes with KRAS G12C inhibitors in treating cancer through the regulation of the FAK\u2013YAP signaling","volume":"8","author":"Zhang","year":"2021","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117593_bib27","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1186\/s13046-021-02154-8","article-title":"Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects","volume":"40","author":"Ilaria","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117593_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2016.86","article-title":"Inhibition of the integrin\/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancy","volume":"6","author":"Xu","year":"2017","journal-title":"Oncogenesis"},{"issue":"1","key":"10.1016\/j.ejmech.2025.117593_bib29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00066-020-01666-0","article-title":"FAK inhibition radiosensitizes pancreatic ductal adenocarcinoma cells in vitro","volume":"197","author":"Mohamed","year":"2020","journal-title":"Strahlenther. Onkol."},{"issue":"661","key":"10.1016\/j.ejmech.2025.117593_bib30","article-title":"Connexins orchestrate progression of breast cancer metastasis to the brain by promoting FAK activation","volume":"14","author":"Girieca Lorusso","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117593_bib31","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1186\/s13046-021-02154-8","article-title":"Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects","volume":"40","author":"Romito","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"116913","key":"10.1016\/j.ejmech.2025.117593_bib32","first-page":"1","article-title":"Development of novel focal adhesion kinase (FAK) inhibitors for targeting cancer: structural insights and therapeutic potential","volume":"279","author":"Li","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"116678","key":"10.1016\/j.ejmech.2025.117593_bib33","first-page":"1","article-title":"Targeting focal adhesion kinase (FAK) in cancer therapy: a recent update on inhibitors and PROTAC degraders","volume":"276","author":"Xiao Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117593_bib34","article-title":"A FAK inhibitor boosts anti-PD1 immunotherapy in a hepatocellular carcinoma mouse model","volume":"12","author":"Yuhua Wei","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117593_bib35","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.drudis.2021.11.025","article-title":"Focal adhesion kinase inhibitors in the treatment of solid tumors: preclinical and clinical evidence","volume":"27","author":"Quispe","year":"2022","journal-title":"Drug Discov. Today"},{"issue":"7","key":"10.1016\/j.ejmech.2025.117593_bib36","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1021\/acs.molpharmaceut.2c00180","article-title":"Design, synthesis, and biological evaluation of 4-arylamino pyrimidine derivatives as FAK inhibitors and tumor radiotracers","volume":"19","author":"Li","year":"2022","journal-title":"Mol. Pharm."},{"issue":"19","key":"10.1016\/j.ejmech.2025.117593_bib37","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.4161\/15384101.2014.949550","article-title":"A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells","volume":"13","author":"Zhang","year":"2014","journal-title":"Cell Cycle"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425003587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425003587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:43:45Z","timestamp":1778042625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425003587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":37,"alternative-id":["S0223523425003587"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117593","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of potent focal adhesion kinase (FAK) inhibitor A8 with enhanced antitumor activity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117593","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117593"}}